cerca CERCA
Sabato 04 Dicembre 2021
Aggiornato: 19:40
Temi caldi


comunicato stampa

Lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic deramatitis in two Phase 3 trials

BARCELONA, Aug. 16, 2021 /PRNewswire/ -- Lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), as measured by EASI*, in ADvocate 1 and ADvocate 2 Phase 3 clinical trials announced today by Almirall S.A. (BME: ALM). In the top-line results from these two monotherapy studies, primary and all key secondary endpoints, including skin clearance and itch improvement, were met at Week 16. Lebrikizum...

ora in
Prima pagina
in Evidenza